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It sounds simple to obtain suﬃcient numbers of cells derived from fetal or adult human tissues, isolate and/or expand the stem
cells, and then transplant an appropriate number of these cells into the patient at the correct location. However, translating basic
research into routine therapies is a complex multistep process which necessitates product regulation. The challenge relates to
managing the expected therapeutic beneﬁts with the potential risks and to balance the fast move to clinical trials with time-
consumingcautious risk assessment.This paper will focus on the deﬁnition of mesenchymal stromal cells (MSCs),and challenges
and achievements in the manufacturing process enabling their use in clinical studies. It will allude to diﬀerent cellular sources,
special capacities of MSCs, but also to current regulations, with a special focus on accessory material of human or animal origin,
like media supplements. As cellular integrity and purity, formulation and lot release testing of the ﬁnal product, validation of all
procedures, and quality assurance are of utmost necessity, these topics will be addressed.
1.Mesenchymal StromalCellsin
CellularTherapies
The vision for cellular therapies in regenerative medicine
seems obvious: to replace diseased, dying, or missing cells
or tissues with healthy cells [1]. The role of stem cells in
this respect is under intense scrutiny, to deﬁne principles of
organ regenerationand to developinnovative novel methods
to treat organ failure. Mesenchymal stem or stromal cells
(MSCs) emerge as key candidates for cellular therapies,
covering regenerative and immune therapies.
MSCs have a great appeal for cell and immune therapy
and tissue engineering for numerous reasons:
(1) they are relatively easy to procure from a variety of
tissues [2];
(2) they expand rapidly in cell culture [3];
(3) they show only minor spontaneous diﬀerentiation
during ex vivo expansion [4];
(4) they are multipotent [4, 5];
(5) they form supportive stroma for hematopoiesis and
support hematopoietic stem cell engraftment [6];
(6) theyseemtobelargelyimmunologicallyinert,paving
the way for allogeneic transplantations [7];
(7) they are immunosuppressive [8];
(8) they secrete numerous trophic factors which modu-
late inﬂammation, remodelling, and apoptosis [9].
Based on the initial work of Friedenstein and Caplan,
bone marrow-derived MSCs (BM-MSCs) are the ones best
described and most advanced in clinical settings. In most
comparative studies, BM-MSCs serve as gold standard [2].
For therapeutic applications, easily accessible and highly
abundant sources are advantageous. Adipose tissue (AT),
most often obtained as lipoaspirate, has emerged as an
alternative tissue because cells occur at high frequency and
the procurement is less invasive than that of BM aspiration
[2].Bloodisobviouslythemost accessibleadulttissue source
for cells. Peripheral blood, however, does not contain MSCs
in a nonpathological setting, at least not in numbers relevant
for clinical scale manufacturing [10]. The same ﬁndings still2 Stem Cells International
hold true for umbilical cord blood (CB) [2, 11]. An inverse
correlation between the gestational age and yields of MSCs is
described[12].ThusMSCsinfulltermCBarepresentatonly
low frequencies which hamper the isolation success [2, 11,
13]. In contrast to CB, isolation success is guaranteed when
using the umbilical cord matrix or Wharton’s jelly [14]. Fetal
tissues are interesting as they seem to contain comparatively
immature MSCs expressing pluripotency markers like SSEA-
3, and 4, Oct-4, Sox-2 and Nanog [15].
2.TowardsClinical-Scale
Manufacturingof MSCs
MSCs are increasingly used in many preclinical as well as
in some clinical settings for immunomodulation or tissue
repair as summarised in more detail in theadjoining sections
of this special issue. It is important to note that up to date
administrationofMSCsprovedtobesafeandalsoeﬃcacious
in a variety of disorders [16]. Several of these disorders are
characterized byboth inﬂammation and tissue defects.Often
itcannotbedissectedwhethereﬃcacyofMSCsisduetotheir
production of trophic factors which stimulate endogenous
repair mechanisms, their direct diﬀerentiation into various
cell types or their immunomodulatory eﬀects. Insome of the
models, factors released by the MSCs are obviously suﬃcient
to mount a substantial part of the eﬀect [9]. Thus whether
eﬃcacy of MSCs requires long-term persistence of MSCs
remains to be elucidated.
Translating the rapid progress in stem cell science into
innovativecellulartherapiesledtoearlyandlatestageclinical
trials. However the complexity of the translational process
rangingfromtheconception,toadvancedclinicaltestingand
ﬁnally new cell therapeutic drugs revealed a lag behind of
standards and guidelines and often suﬀer from a regulatory
burden. Increased scrutiny by the regulatory authorities is
mutually dependent from the increasing numbers of cell
therapyclinicaltrials.Avarietyoforganisationsrespondedto
that threat to propose minimal set of standards or consensus
guidelines [17–21].
Controversies about characteristics and potencies exist
most probably due to the fact that diﬀerent laboratories
employ not only diﬀerent tissue sources, but also extraction
methods, culture protocols, and characterisation tools. Any
variation may result in isolation and expansion of diﬀerent
subpopulations of cells or may change characteristics of the
cells [22]. Thus Dominici et al. proposed minimal criteria
deﬁning MSCs [17], namely,
(1) adherence to plastic under standard culture condi-
tions,
(2) expression of CD105, CD73, and CD90, and lack
of expression of CD45, CD34, CD14, or CD11b,
CD79alphaorCD19andHLA-DRsurface molecules,
(3) diﬀerentiation to osteoblasts, adipocytes, and chon-
droblasts in vitro.
Given the fact that even MSCs used in clinical trials
are produced and characterised by a variety of diﬀerent
protocols, reproduction or interpretation of the clinical
results may be hampered [21]. Accordingly, standardized
protocols have to be developed assuring that the manufac-
tured cells behave solely in the clinically intended purpose
anddonotexertadverseeﬀectsby,forexample,uncontrolled
diﬀerentiation or transformation. Typically MSC can be cul-
tured for 40–50 population doublings until the growth rate
declinessigniﬁcantlyandcellsundergoreplicativesenescence
[23]. Under certain conditions, however, MSCs have been
observed to transform spontaneously. Discrepancies were
resolved, when laboratories reported that transformation of
MSCs was caused by cross-contamination with tumor cell
lines [24, 25].
Therefore, an essential requirement is that all steps in
MSC manufacturing from starting material up to potency
testing for the intended indication have to be highly
standardized to assure a required and reproducible cellular
quality and potency. The challenge for scientists aiming
at producing MSCs for clinical trials is to deﬁne opti-
mal cell culture conditions to eﬃciently isolate and ex
vivo expand homogenous MSCs while maintaining cellular
qualities required for the intended clinical application and
minimising risks of adverse events. For example, we recently
v e r i ﬁ e dw h e t h e rA T - M S C si s o l a t e da n de x p a n d e di nh u m a n
serum (HS) share characteristics with cells cultivated in
fetal bovine serum (FBS) [22, 26]. Although all criteria
deﬁned in [17] have been fulﬁlled, minimal diﬀerences were
obvious regarding cell size and gene expression proﬁles. By
comparingtwohumansupplementstoFBS,weobservedthat
FBS alters gene expression slightly, but in genes categorized
to diﬀerentiation and adhesion/extracellular matrix [22].
Current studies focus on dissecting in detail whether the
supplements alter cellular behaviour in a way aﬀecting the
intended therapeutic application.
The therapeutic aim is to repair cell or tissue damage
but without the risk of inducing tumors, severe immune
reactions, or unwanted tissue development. Thus both
safety and eﬃcacy measures shall be considered in the
establishment of the manufacturing process. Scarcity of
MSCs often requires ex vivo expansion; extensive expansion
in consequence may lead to ineﬀective or degenerated cells
[23].Thusitisimportanttounderstandandcarefullycontrol
the production process and accordingly to deﬁne measures
that reliably predict safety and eﬃcacy of cell therapeutics.
3.RegulatoryFrameworks
The employment of adult stem cell types in clinical studies,
in general, necessitates formal approval by the respective
regulatory body. This approval requires manufacturing,
processing, and testing of cellular products according to the
current national regulations, including current good tissue
practice (GTP), good manufacturing practice (GMP) and
good clinical practice (GCP). All cell-based products shall
comply with these rules to ensure the product is safe, pure,
and potent. GTP and GMP refer to common standards,
regulating facilities, personnel, equipment, reagents and
supplies, procedures and ﬁnally controls (process, ﬁnal
product and laboratory controls). These standards shouldStem Cells International 3
be considered as soon as the development of a cellular
product begins. For that reason, regulatory authorities oﬀer
investigators their advice to ﬁne-tune the process from the
early beginning on.
In Europe, MSCs are classiﬁed as advanced therapy
medicinal products (ATMPs) [27, 28]. ATMPs include
gene therapy medicinal products, somatic cell therapy
products (as deﬁned in Directive 2001/83/EC), and tissue-
engineered products. Cells fall under this regulation in
case they have been subjected to substantial manipulation,
resulting in a change of their biological characteristics,
physiological functions or structural properties relevant
for the intended therapeutic application, for example,
regeneration, repair, or replacement. ATMP refers to cells
or tissues that are not intended to be used for the same
essential functions in the recipient as in the donor. This
means that MSCs can be considered as somatic cell therapy
products or tissue-engineered products depending on the
indication and the manipulation during the manufacturing
process. Concerning clinical trials with MSCs the rules set
out in Article 6(7) and Article 9(4) and (6) of Directive
2001/20/EC shall apply. In the EU the responsible body
for clinical trials approval are the health authorities at
national level. This is in contrast to USA, where the NIH
takes over this part [28, 29]. In the EU, GMP and GCP are
more interrelated than in USA. The European Regulation
No. 1394/2007 is eﬀective since December 2008 and is
binding in its entirety and directly applicable in all Member
States. (Regulation (EC) No 1394/2007 of the European
Parliament and of the council http://ec.europa.eu/health/
human-use/advanced-therapies/index en.htm.T h em a i n
elements are (i) a centralised marketing authorisation
procedure, (ii) the committee for advanced therapies (CAT)
as multidisciplinary scientiﬁc committed to review the
quality, safety and regulatory aspects of ATMP, (iii) technical
requirements adapted to particular ATMP characteristics
incentives for small- and medium-sized enterprises.) It is
in compliance with the 2004/23/EC directive on donation,
procurement and testing of human cells and tissues and
with the directive 2002/98/EC on human blood and blood
components. It is amending the Guideline on cell-based
medicinal products (EMEA/CHMP/410869/2006) which
focuses on the manufacturing and quality control of cell-
based medicinal products as well as their nonclinical and
clinical development.
In the US, the FDA (Food and Drug Administration)
announced in 1997 the “Proposed Approach to Regulation
of Cellular and Tissue-Based Products” (21 CFR 1271).
(http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/
CFRSearch.cfm?CFRPart=1271. Sec. 1271.1: “The purpose
ofthispart,...,istocreateauniﬁedregistrationandlisting
system for establishments that manufacture human cells,
tissues, and cellular and tissue-based products (HCT/P’s)
and to establish donor-eligibility, current good tissue
practice, and other procedures to prevent the introduction,
transmission, and spread of communicable diseases by
HCT/P’s”.) This became eﬀective in 2005 as rules for
Human Cells, Tissues, and Cellular and Tissue-Based
Products (HCT/Ps). Although only one cell-based product
(Carticel, autologous cell-based product for cartilage repair
manufactured by Genzyme) has been licensed by the
FDA, this does not reﬂect the actual number of trials with
cell-based products. Those cell-based therapeutics do not
require FDA-approval “that are minimally manipulated,
labeled or advertised for homologous use only, and not
combined with a drug or device” as speciﬁed by Parson,
[30]. In contrast, manipulated autologous cells for structural
use meet the deﬁnition of somatic cell therapy products
and require an “investigational new drug” (IND) exemption
or the FDA-license approval. In 2007 the “Guidance
for Industry: Regulation of Human Cells, Tissues, and
Cellular and Tissue-Based Products (HCT/Ps)—Small
Entity Compliance Guide” and in 2009 the “Guidance for
Industry on Current Good Tissue Practice (cGTP) and
Additional Requirements for Manufacturers of Human
Cells, Tissues and Cellular and Tissue-based Products”
(http://www.fda.gov) have been released. The FDA provides
recommendations to support manufacturing establishments
of HCT/Ps to better understand and comply with the
regulatory framework. Clinical studies employing MSCs
underlie the IND mechanism. Accordingly investigator have
to make an IND application, which necessitates detailed
study protocols, describing the clinical plan as well as the
preparation and testing of the therapeutic cell product [31].
Both regulatory frameworks in the EU and USA are to
assure safety and thus they require a thorough analysis of
all critical steps and aspects in advance. Although there are
still diﬀerences [19, 28, 29], the authorities are in contact
to further harmonise them. Thus it can be expected that by
serving the requirements of one community, the chance is
high to fulﬁl the others as well.
In the following parameters relevant for the manufacture
of MSCs are exempliﬁed.
4.ManufacturingProcess
The manufacturing process is highly fragmented as exempli-
ﬁed in Figure 1, illustrating a GMP-compliant MSC man-
ufacturing process with processing and testing steps. Thus
it should be well established and validated before initiating
pivotal clinical trials because changes in the manufacturing
process may confound clinical trial results.
4.1. Tissue Procurement. In general, the starting material
is a critical issue and includes common donor eligibility
criteria, like age and viral testing. MSCs have been applied in
autologous and allogeneic settings and derived from various
tissue sources. Due to an immuno privileged status, a single
allogeneic MSC donor may serve for multiple recipients
raising the demand for well-deﬁned eligibility criteria [32].
The most often used cellular source to obtain MSCs is
BM, followed by AT and then other tissue sources, where
we will herein focus on perinatal tissues. BM-derived MSCs
are harvested via BM aspiration after puncture of the donors
iliac crest. Aspiration strategy and volume impact the yield
of MSCs, so that multiple aspirations from the same site
and low aspiration volume (<8mL) should be avoided [33].4 Stem Cells International
Processing Assessments/testing
Day 0
Cell or tissue procurement
transport
Media change
Discard contaminating cells
Cryopreservation
Packaging
Labeling
Shipment
Media change
every 3 to 4days
Media change
every 3 to 4days
Day 0
Product receipt
Donor testing
Initiate processing
Monitor cell growth
Verify lack of contamination
Visual inspection of morphology
Count viable cells
Sterility testing
Day 1–3
Day 1–3
Day 10–14
Day 10–14
Day 14—ﬁnal harvest Day 14—ﬁnal harvest
Final product release criteria Passage at max. 70% conﬂuency
Harvest
Cell isolation
Initiation of culture
or storage or direct application
Verify donor screening
Passage at max. 70% conﬂuency
Harvest or
reseed cells
Store retention samples, when possible
Store retention samples, when possible Sterility, mycoplasma, endotoxin, morphology,
cell dose, viability, identity, potency
Storage or transport to clinical site
Figure 1:Flowchartillustratingessentialprocessingandtestingsteps duringMSCmanufacture. ThisschemesummarisesaGMP-compliant
manufacturing process of MSC expansion separated into processing and related testing activities. On day zero the tissue is harvested and
transported to the processing lab. Here donor eligibility criteria are checked again and donor testing/reception control initiated (viral,
bacterial, blood group, condition, weight, if applicable cell counting, etc.). Veriﬁed reception control is a prerequisite for starting processing
in the GMP facility. Here cell isolation is performed and expansion cultures initiated or the product is directly applied to the patient.
Predeﬁned in-process controls shall be taken at any critical processing step to verify cellular qualities and sterility. If expansion is initiated,
normal protocols include a medium exchange step concomitantly depleting contaminating cells. Cell growth can be monitored visually as
well as potentialcontamination.Passagingofthecells canbe performed withinthe next 14days involvingcontrols formorphology, viability,
and sterility. Assuming day 14 for the day of harvest and product release, cells have to be speciﬁed against predeﬁned ﬁnal product release
criteria. The product can then be cryopreserved allowing for additional potency assays or directly transported to the recipient. Packaging,
labeling, and shipment conditions again have to follow GMP rules.Stem Cells International 5
Further hints indicate that donor age impacts the cell yield
and the diﬀerentiation potential of MSCs [34, 35]. Aspirated
BM volume can be a critical issue as high volumes can
result in dilution with blood, too low volumes however
demonstrated low to highly heterogeneous yields of MSCs
[33]. Some data indicate that MSCs can be isolated from
themarrow ﬁlterwashouts dedicatedforhematopoieticstem
cell procurement [36]. For isolation, most protocols employ
density gradient centrifugation, although the necessity for
this step is debated and still under optimisation [37].
Mononuclear cells are then cultivated in MSC culture media
until ﬁbroblastoid cells show outgrowth.
AT represents an accessible source of MSCs, often
referred to as adipose stem cells (ASCs) [38]. AT can
be procured by diﬀerent techniques, including excision or
aspiration, from regions of the body where it is largely
present (abdomen, trochanter region, groin, knee). MSCs
can be isolated from the tissue by collagenase digestion
and centrifugation and cultivation of the stromal vascular
fraction to give rise to MSCs[2].Variousstudiesanalysed the
impact of harvesting conditions to the cell yield. The yield of
ASCdoesnot seem to be aﬀected by the aspiration technique
comparing syringe-based or pump-assisted liposuction [39],
still there seem to be signiﬁcant diﬀerences between the
harvesting sites concerning the adipogenic properties [40]
and their susceptibility to apoptosis [41].Regarding the yield
of the harvested ASC, there are controversial results: some
report a richer yield of nucleated cells and colony forming
units in hip versus abdominal liposuction [39], some others
a superior yield of colony forming units after abdominal
liposuction compared to hip liposuction [42].
In studies comparing liposuction versus tissue excision,
liposuction method turns out to be superior as the cell
yield in aspiration material remains stable even after 24h
storage in contrary to the decreasing cell yield of excisates.
In contrast to these results a latter study reveals a higher cell
yield and viability after excision [43].
Concerning the inﬂuence of the negative pressure during
liposuction negative pressure of −350mmHg leads to a
greater cell yield than lower pressure of −700mmHg [44].
Postnatal gestational tissues inherit numerous advan-
tages over MSCs derived from aged adult tissues. Early focus
on perinatal tissues harbouring stem cells arose from HSC
and MSCs identiﬁed in CB [11, 45]. Subsequently fetal
liver, lung, brain, but also villous placenta, fetal membranes
as well as amniotic ﬂuid were identiﬁed to host MSCs
[13, 15]. Not discussing abortal tissues, in the majority
of cases perinatal tissues are discarded at birth, thus cells
harvestable without any risk for the baby or its mother.
Consequently, there is an unlimited supply, easy access,
and minimal ethical/legal issues associated with perinatal
tissues. Tissues canbe stored forautologoususe orallogeneic
settings as fetal cells have been demonstrated to be immuno-
privileged. Hence CB storage is one strategy widely followed
in numerous countries, not only for allogeneic, but also for
potential autologous applications [46].
4.2. Manufacture at the Bedside: Volume Reduction and Direct
Application. Some therapeutic applications, for example,
in cardiac cell therapy, use solely minimally processed
tissues, like volume reduced mononuclear cells which can
be performed at the patients bedside [47]. This suggests
an attractive and probably cost and time reducing option
for autologous therapeutic settings and fall under diﬀerent
regulations (the ATMP so-called “hospital exemption”)
(“Any advanced therapy medicinal product, as deﬁned in
Regulation (EC) No 1394/2007, which is prepared on a
nonroutine basis according to speciﬁc quality standards,
and used within the same Member State in a hospital
under the exclusive professional responsibility of a medical
practitioner, in order to comply with an individual medical
prescription for a custom-made product for an individual
patient.” (EU regulation 1394/2007)). Due to the high
precursor frequency especially AT can be processed at the
patients’ bedside [48]. Still there are diﬀerent aspects that
have to be considered in order to minimize the risks of
cellular therapy [49, 50]. But minimally processed tissues
contain a large heterogeneous mixture of stem, progenitor
cells, and mature cells, thus of suboptimal composition [51].
A few studies comparing volume reduced to expanded AT-
derived cell preparations revealed diﬀerent results [52, 53].
Consequently, to the current date all clinical applications
specifying theuseofMSCshavebeenusing cultureexpanded
cells.
4.3. Manufacture in a GMP-Facility
4.3.1. Isolation and Expansion. In order to fulﬁl the regula-
tory standards the manufacture of a cell product requires
the use of safe and pure components and materials. If
possible, licensed or GMP-grade reagents should be used, in
case of research-grade reagents additional in-house testing
may be required to ensure safety and quality. Reagents,
including supplements, cytokines, growth factors, used for
expansion or diﬀerentiation of MSCs should be controlled
and documented. Several parameters for ex vivo expansion
of MSCs are critical to ensure both good expansion rates as
wellasmaintenanceofmultipotencyofMSCs.Theseinclude,
for example, starting material, methods used for enrichment
or separation, plating density, devices used for MSC culture,
media, supplements and growth factors as well as passage
number or population doublings [54].
4.3.2. Cell Seeding. Plating densities have emerged as a
critical issue for MSC isolation and expansion. Low seeding
densities in primary culture seem to be associated with
the emergence of more immature progenitor subsets [3].
Moreover, seeding at low densities allows higher expansion
rates. For scale-up, accordingly, two diﬀerent protocols are
proposed. In one protocol cells are seeded at nearly clonal
levels. This allows expanding the cells to high cumulative
population doublings within one passage, but requires large
culture area [55]. The other protocol seeds cells at higher
concentrations. Due to reduced possible population dou-
blings, this procedure necessitates a second passage, which,
however, facilitates eﬃcient depletion of contaminating cells
[56].6 Stem Cells International
4.3.3. Media and Supplements. Culture conditions shall
retain or even accelerate regenerative and trophic properties
of MSCs. The variety in protocols is immense and a
standard has not yet been deﬁned. The classical media
composition consists of a basal medium (DMEM or alpha-
MEM) and 10%–20% supplement, most often FBS, which
is available in GMP grade allowed for clinical use. The
ongoing debate regarding xenogenic, especially ruminant
proteins in pharmaceuticals also applies to MSCs. FBS bears
the risk of transferring xenogenic, potentially infectious,
or immunogenic proteins. Immunogenicity against FBS
proteins has demonstrated to compromise the therapeutic
beneﬁt [57, 58]. Thus although GMP-compliant FBS batches
are available and used in clinical grade manufacturing the
regulatory authorities ask to replace FBS with a nonxeno-
geneic alternative if possible for the manufacturer.
Up to now no completely serum-free media formulation
in clinical-grade is available which allows both isolation
(critical issue: attachment factors) and expansion of MSC
[59]. Serum proteins provide not only nutrients but also
essential attachment factors. Several laboratories have pro-
posed the use of human components to supplement MSC
growth medium. Here either autologous or allogeneic HS or
platelet-derived factors have been evaluated [26, 54, 59, 60].
HS as well as platelet lysate are very crude protein cocktails.
Essential growth factors for optimal MSC culture have not
yet been deﬁned. PDGF, EGF, TGF-β, and IGF have been
subjected to investigation. Basic FGF has demonstrated most
promising eﬀects in expanding MSCs whilst maintaining
stemcell properties and reducing replicativesenescence [61].
Recently, Pytl´ ık et al. described a HS and growth factor
supplementedclinical-grademediumwhich allowed forhigh
cell expansion mediated by loss of contact inhibition [62].
Any signiﬁcant change in the production process may
aﬀect cellular functions. Accordingly, it is necessary to
analyse the qualities of MSCs in comparability studies to
ensure that cellular qualities are not compromised. Within
a variety of publications, pooled human platelet lysate
emerged as suitable alternative for BM-MSC isolation and
expansion [26]. Our own data indicate that for ASC in
contrast pooled HS has better eﬀects on expansion [60].
But as speciﬁed above, it has to be determined whether
therapeutic qualities are modiﬁed, improved or impaired. It
is conceivable that depending on the clinical setting diﬀerent
protocols (cellular sources, manufacturing protocols, quality
control/potencyassays) comeintoplacetoderivetheoptimal
product.
4.3.4. Devices for Expansion. MSCs grow as adherent cells
until reaching conﬂuency and then further expand by serial
passaging. Therefore the number of cells which can be har-
vested in an ex vivo expansion culture is determined by the
surface area. Typically MSCs are cultivated in conventional
monolayer cultures. In order to achieve a large surface area
multilayered cell factories are used [55, 56]. This approach
is labour intensive and money consuming. Also by using
bioreactors it became possible to expand MSCs [63, 64].
As closed systems should be preferred in a GMP-setting,
Rojewski et al. report a fully automated bioreactor allowing
large-scale GMP-compliant manufacturing [65].
A critical issue is the proliferative age of MSCs: MSCs
have a restricted lifespan and reach a senescent state in which
cellular functions become diminished and the risk for accu-
mulating mutations rises [32, 66]. Most often proliferative
capacity is expressed by passage numbers. Passage numbers
in contrast to population doublings do not describe the de
facto proliferation history which is critical when reaching
a certain—not yet well—deﬁned time point (maximum 30
population doublings) [66].
4.3.5. Storage or Cryopreservation. After isolation, volume-
reduced cells or ex vivo-culture expanded cells can be
transplanted directly or stored for long term under low
temperature conditions. A variety of studies investigated the
eﬀects of storage conditions and cryopreservation meth-
ods and media [67–69] demonstrating that MSCs can be
cryopreserved and thawed without loss of function [70].
Cryopreservation gives the only opportunity to perform
time-consuming release tests prior to clinical application of
the cells, hardly possible to achieve when the cell product is
intended for immediate release.
4.4. Product Speciﬁcation. As always it is necessary to weigh
carefully the risk against the potential beneﬁts of stem
cell therapy. Potential risks can be reduced when applying
appropriate release tests capable of ensuring safety, eﬃcacy
and consistency of the product. Cell-based products require
special considerations on the manufacturing process, espe-
cially when they have to be applied immediately. In this
situation it is impossible to obtain results of laboratory tests
prior to the cell application, thus a limited set of controls has
to ensure that the product fulﬁls all the predeﬁned quality
criteria. For cellular products in general suﬃcient numbers
of viable, high quality cells are required. These can be easily
documented by simple, rapid cell viability tests.
Cell-based products cannot be sterilized to avoid trans-
ferringinfectiousdiseases.Byusinghumanand/orxenogenic
material, there is a potential for adventitious agent con-
tamination, thus testing for bacteria, fungi, mycoplasma
and viruses should be performed. Regardless of the use in
autologous or allogeneic settings an increased attention to
assure aseptic processing is mandatory.
As indicated above, safety might be aﬀected as pro-
longed ex vivo culture can accumulate aberrations. But
only anecdotal studies indicate that MSCs may undergo
spontaneous transformation, associated with chromosomal
aberrations,inductionofoncogenesandtumorigenicityafter
transplantation [23, 71]. Clinical experience indicates that
cells, when harvested before onset of senescence, demon-
strate extremely low probability of tumor formation [66].
Current testing systems including karyotype analyses, FISH,
comparative genomic hybridization, or PCR to check for
tumor marker expression may not be sensitive enough to
detect the expected low proportion of aﬀected cells [72],
but even occurrence of alterations, like aneuploidity does
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Tarte et al. These data nevertheless helped to reﬁne control
assays, easily to perform, to control cell cycle/senescence
and transformation pathways by, for example, PCR for p14,
p16Ink4a, p21, p53, hTERT, and oncogenes like c-myc.
Further clinical safety concerns relate to possible ectopic
tissue formation or other adverse events in the recipient.
Despite the fact that in general no adverse reactions have
been recorded, this possibility cannot be neglected yet.
Mice treated locally with MSCs for myocardial infarction
developed calciﬁcations [73]. Further the relatively big cell
size has been observed at times to cause pulmonary seques-
tration and embolism after intravascular transplantation
[74]. Furthermore the protocol for cell application can aﬀect
transplantation as recently demonstrated when comparing
diﬀerent cell suspension media [75]. Finally, although thera-
peutically intended in some clinical settings, for example, to
prevent or treat GvHD, the immunomodulatory capacities
may also favour tumor growth or formation of metastasis, as
observed in animal models [76–79].
For the EU and USA, the criteria for test procedures
diﬀer. Test procedures, for example, for sterility test, have
to be approved by the FDA or the national regulatory
authorities in Europe. But as the requirements are not
identical, the international conference of harmonisation
(ICH)intendstoharmonise them(formoreinformation,see
respective homepages).
4.5. Identity and Impurities. The identity of cell-based
products can be ensured where necessary by genotypic
or phenotypic analysis. In MSC cultures, the fraction of
cells displaying identity markers (mesenchymal markers)
and the identiﬁcation of contaminating cells (hematopoietic
markers) can be easily and rapidly quantiﬁed by ﬂow
cytometric analyses [17, 80]. Above this morphological
assessment of ﬁbroblastic phenotype and proliferation can
be easily documented in expansion cultures.
Product-related impurities have to be determined and
speciﬁed, including endotoxin testing [81]. Where appropri-
ate,impuritiesrelatingto,forexample, degradationproducts
from structural or matrix components shall be speciﬁed,
as well as process-related impurities derived from added
bioactive components.
4.6. Potency. Product characterisation has to consider the
functional capacities related to the intended clinical use. The
minimal criteria of the ISCT require to control the capacity
of MSCs to adhere to normal plastic culture surfaces, to
generate cells with a ﬁbroblastic phenotype, which express
or fail to express a typical set of surface markers, and
to exhibit multilineage diﬀerentiation potential, at least
into the osteo-, adipo-, and chondrogenic lineage [17].
Although every laboratory employs these assays, the assays
are time consuming and far from being standardized yet,
so comparison between laboratories and also the read-out
of clinical data is hampered [80]. As mentioned before
development of preclinical eﬃcacy tests in the investigated
indication are highly desirable as MSCs appear to employ
diﬀerent modes of function according to the intended use.
Depending on the clinical intention, the following assays can
be performed to assess potency, but it has to be kept in
mind that none of these assays has been directly correlated
to therapeutic eﬃciency [32].
Clonogenicity. The CFU-F assay is a suitable but not stan-
dardized tool to quantify precursor frequencies. Analysis
demands for appropriate dilution to clonal levels as CFU-F
frequenciesdonotfollow a linearregression correlated tothe
input cell number [54, 55].
Diﬀerentiation Potential. The multilineage diﬀerentiation
potential is a hallmark of MSCs, but discussed in detail
elsewhere [4, 5, 82]. In vitro assays can be performed
using self-made or commercially available induction media.
However, it is increasingly discussed whether and to which
extent in vitro data correlate to in vivo diﬀerentiation
potential [82, 83].
Immunomodulatory Capacities. The perspective of modu-
lating immune responses against allo- and possible also
autoantigens has rendered MSCs an attractive population
of cells for immune therapies. In vitro, assays have been
established to quantify the expression of surface molecules,
such as HLA class I and II and costimulatory molecules. In
cocultures with peripheral blood mononuclear cells, MSCs
do not elicit an alloreactive response. Furthermore, when
added as third party in mixed lymphocyte reactions or
mitogen-driven cultures, MSCs dose dependently inhibit
immune cell responses. Very low concentrations of MSCs
however can stimulate immune responses [84]. While this
has not yet been observed in vivo, too low numbers of
MSCs transplanted may accelerate the immune response
rather than mitigate it in GvHD or autoimmune set-
tings.
Hematopoiesis/Stromal Support. The beneﬁcial eﬀects of co-
transplanting MSCs in haematological settings have already
been demonstrated [85]. This eﬀect can be assayed in vitro
in coculture experiments using hematopoietic stem cells and
MSCs and thus may be an adequate quality control system
for this therapeutic indication [86].
Trophic Support. I nav a r i e t yo fs e t t i n g sM S C ss h o w e d
promising therapeutic eﬀects even though the transfused
cells were—if at all—only barely detectable in the injured
organs. Recent data further demonstrated that especially
secreted factors actively modulate debilitating local inﬂam-
matory reactions. Reduction of apoptosis, and ﬁbrotic
tissue remodelling as well as recruitment of local resident
regenerative cells contributed to the beneﬁcial eﬀects [9, 87].
Accordingly some studies already demonstrate therapeutic
eﬀects when infusing MSC conditioned medium instead
of cells [88, 89]. Depending on the therapeutical setting,
analysing the secretome by quantifying levels of chemo- or
cytokines may subsequently emerge as additional potency
assay [26, 60].8 Stem Cells International
4.7. Validation. Safety and eﬃcacy of a cellular product has
to be demonstrated prior to their administration in humans.
MSC application in clinical settings has progressed fast
with 128 hits entering “mesenchymal stem cells” as search
term under http://www.clinicaltrials.org. Nevertheless, there
is a trend to go back from bedside to bench to bet-
ter characterise and improve MSCs and importantly to
standardise protocols for isolation, expansion, and ﬁnally
characterisation. Changes in vitro necessitate translating
them into clinical protocols. Thus it is a critical point to
coordinatethecliniciansneedswith theresearchers optionin
close interaction with the manufacturing laboratories, who
overview the margin framed by the regulatory authorities.
Any signiﬁcant changes in the manufacturing protocols
require validation in vitro and in appropriate in vivo
animal models to assure safety and eﬃcacy [28]a sw e l la s
absence of toxicity (related to dediﬀerentiation or unwanted
diﬀerentiation, migration to unwanted sites). All animal
models have inherent limitations, like, for example, the
application of human cells in a xenogenic milieu [82]. This
requires the use of severely immunocompromised small
animals preventing contrariwise analysis of immunological
reactions. Furthermore for a variety of disease models, for
example, in orthopaedics, small animals are not capable of
modelling the disease. Consequently, one has to deﬁne a
compromise between all requirements: clinical, regulatory,
and laboratory to agree on appropriate validation strate-
gies.
5.Conclusion
In the recent years numerous advancements led to
the employment of MSCs in a variety of therapeu-
tic indications raising expectations and hope. Although
numerous clinical trials have been initiated worldwide
(http://clinicaltrials.gov), standardized protocols for isola-
tion, expansion, and characterisation, especially those on
GMP-grade, seem to lag behind. The sum of clinical studies
has supported safety and eﬃcacy by demonstrating absence
of major side eﬀects associated with success reports. The lack
of conformity between manufacturing protocols however
is considered as potential threat to further development
of the ﬁeld. The heterogeneity of isolation, expansion,
and characterisation protocols remains as obstacle. Thus
to ensure the success of MSC-based therapies, we regard
as a major critical issue to standardise and harmonise
translational protocols in order to develop manufacturing
processes along-side with developing therapies and not
thereafter.
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